 |
|
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan
Clin Mol Hepatol. 2021;27(3):474-485. Published online 2021 Feb 19 DOI: https://doi.org/10.3350/cmh.2021.0015
|
|
Citations to this article as recorded by
 Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani
Clinical and Molecular Hepatology.2023; 29(1): 135. CrossRef Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
Jing Hong Loo, Wen Xin Flora Xu, Jun Teck Low, Wei Xuan Tay, Le Shaun Ang, Yew Chong Tam, Prem Harichander Thurairajah, Rahul Kumar, Yu Jun Wong
World Journal of Hepatology.2022; 14(6): 1248. CrossRef HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV
Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
Biomedicines.2022; 10(12): 3152. CrossRef Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers–Led Model for HCV Microelimination in Thailand
Ruamthip Supanan, Win Min Han, Weerakit Harnpariphan, Thornthun Ueaphongsukkit, Sasiwimol Ubolyam, Jiratchaya Sophonphan, Pisit Tangkijvanich, Sombat Thanprasertsuk, Anchalee Avihingsanon
JAIDS Journal of Acquired Immune Deficiency Syndromes.2021; 88(5): 465. CrossRef
|